GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Usana Health Sciences Inc (NYSE:USNA) » Definitions » Piotroski F-Score
中文

Usana Health Sciences (Usana Health Sciences) Piotroski F-Score : 7 (As of Apr. 24, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Usana Health Sciences Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Usana Health Sciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Usana Health Sciences's Piotroski F-Score or its related term are showing as below:

USNA' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Usana Health Sciences was 8. The lowest was 5. And the median was 7.


Usana Health Sciences Piotroski F-Score Historical Data

The historical data trend for Usana Health Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Usana Health Sciences Piotroski F-Score Chart

Usana Health Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 8.00 6.00 6.00 7.00

Usana Health Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 5.00 5.00 7.00

Competitive Comparison of Usana Health Sciences's Piotroski F-Score

For the Packaged Foods subindustry, Usana Health Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Usana Health Sciences's Piotroski F-Score Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Usana Health Sciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 18.383 + 17.292 + 11.347 + 16.766 = $63.8 Mil.
Cash Flow from Operations was 12.833 + 9.551 + 22.234 + 26.023 = $70.6 Mil.
Revenue was 248.36 + 238.202 + 213.365 + 221.083 = $921.0 Mil.
Gross Profit was 199.841 + 194.876 + 170.836 + 178.764 = $744.3 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(596.549 + 605.533 + 602.68 + 601.148 + 632.757) / 5 = $607.7334 Mil.
Total Assets at the begining of this year (Dec22) was $596.5 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Total Current Assets was $417.7 Mil.
Total Current Liabilities was $118.8 Mil.
Net Income was 22.469 + 19.157 + 14.929 + 12.795 = $69.4 Mil.

Revenue was 272.867 + 264.474 + 233.3 + 227.96 = $998.6 Mil.
Gross Profit was 221.484 + 214.957 + 186.74 + 181.53 = $804.7 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(577.74 + 572.919 + 557.959 + 556.063 + 596.549) / 5 = $572.246 Mil.
Total Assets at the begining of last year (Dec21) was $577.7 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Total Current Assets was $384.4 Mil.
Total Current Liabilities was $143.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Usana Health Sciences's current Net Income (TTM) was 63.8. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Usana Health Sciences's current Cash Flow from Operations (TTM) was 70.6. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=63.788/596.549
=0.10692835

ROA (Last Year)=Net Income/Total Assets (Dec21)
=69.35/577.74
=0.12003669

Usana Health Sciences's return on assets of this year was 0.10692835. Usana Health Sciences's return on assets of last year was 0.12003669. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Usana Health Sciences's current Net Income (TTM) was 63.8. Usana Health Sciences's current Cash Flow from Operations (TTM) was 70.6. ==> 70.6 > 63.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0/607.7334
=0

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0/572.246
=0

Usana Health Sciences's gearing of this year was 0. Usana Health Sciences's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=417.746/118.845
=3.51504901

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=384.382/143.833
=2.67241871

Usana Health Sciences's current ratio of this year was 3.51504901. Usana Health Sciences's current ratio of last year was 2.67241871. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Usana Health Sciences's number of shares in issue this year was 19.252. Usana Health Sciences's number of shares in issue last year was 19.265. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=744.317/921.01
=0.80815301

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=804.711/998.601
=0.80583837

Usana Health Sciences's gross margin of this year was 0.80815301. Usana Health Sciences's gross margin of last year was 0.80583837. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=921.01/596.549
=1.54389665

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=998.601/577.74
=1.7284609

Usana Health Sciences's asset turnover of this year was 1.54389665. Usana Health Sciences's asset turnover of last year was 1.7284609. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Usana Health Sciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Usana Health Sciences  (NYSE:USNA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Usana Health Sciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Usana Health Sciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Usana Health Sciences (Usana Health Sciences) Business Description

Traded in Other Exchanges
Address
3838 West Parkway Boulevard, Salt Lake City, UT, USA, 84120
Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.
Executives
John Turman Fleming director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Gilbert A Fuller officer: CFO and Executive V.P. 55 WANDERWOOD WAY, SANDY UT 84092
Frederic J Winssinger director 2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018
David Mulham Mulham officer: Chief Field Development Office 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Paul A. Jones officer: CFO 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Xia Ding director 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Daniel A. Macuga officer: Chief Communications Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Jim Brown officer: Chief Production Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Brent Neidig officer: CO & Man. Dir. of China 3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120
J Scott Nixon director 757 EAST SOUTH TEMPLE, SUITE 150, SALT LAKE CITY UT 84102
Kevin Guest officer: E.V.P. of Marketing 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Joshua Foukas officer: Chief Legal Officer 3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120
G Doug Iiekking officer: VP of Finance C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
Walter Noot officer: Chief Information Officer 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Robert A Sinnott officer: Chief Scientific Officer 400 55 WATER STREET, VANCOUVER A1 V6B1A1